95%
Share of digital health exits (2025–YTD 2026) completed via M&A (268 of 282 exits).
Key Insights
- M&A is the market default: Acquisitions represent 268 of 282 digital health exits (95%) from 2025 to June 2026. IPOs remain selective, requiring clinical evidence and commercial scale, meaning strategic acquisition is the realistic liquidity path for most ventures.
- North America leads, Europe supports: The USA accounts for 68% of exits. Europe — led by the UK, Germany, and France — represents 20%, while APAC remains a secondary market at 10%.
- Infrastructure and care delivery attract buyers: Health Management Solutions leads all clusters with 60 exits since Jan 2025. Patient Solutions, Medical Diagnostics, and Population Health Management follow, confirming that buyers are targeting scale and workflow, not point solutions.
- Time to exit has risen to a 9-year median: Cohorts founded between 2016 and 2020 are entering the peak exit window, and the pipeline for 2027 to 2029 exits is already in formation.
- Roche/PathAI is the neutrality warning shot: Roche’s $1.05 billion acquisition of PathAI turns a neutral pathology AI platform into an owned Roche asset. Its ten pharma partners — including Gilead, MSD, Novo Nordisk and GSK — face a governance decision they cannot defer.
Companies & Ventures Featured in the Report
Google Cloud, Microsoft, Oracle Cerner, Epic Systems, Menlo Ventures, General Catalyst, Bessemer Venture Partners, Flare Capital Partners, Andreessen Horowitz (a16z), F-Prime Capital, Chamber Cardio, House Rx, Qualified Health, Hippocratic AI, WellBeam, Aledade, Abridge, CMR Surgical, Airstrip Technologies, WHOOP, Harbinger Health, Universal Diagnostics, Midi Health, Zarminali Health.
Why You Need This Report
- Investors: Convert compressed paper markups into realised DPI by understanding which exit routes, clusters, and capital-efficiency profiles strategic acquirers are actually rewarding in 2026.
- Pharma & Corporates: Treat vendor acquisition as a governance trigger — map dependency exposure, build change-of-control provisions into vendor contracts, and learn how Roche/PathAI is reshaping the question of who controls critical infrastructure next.
- Digital Health Ventures: Build for trust, evidence, and acquirability — understand what capital-efficient, exit-ready positioning looks like when the median M&A exit follows a $7.7M last funding round.
About the Data
Unless otherwise stated, all data are exclusively sourced from HealthTech Alpha, Galen Growth’s AI-native Digital Health intelligence platform, which continuously monitors, structures, and audits data points across the global ecosystem. HealthTech Alpha tracks 16,000-plus Digital Health ventures across funding, partnerships, evidence, regulatory activity, and products.
The 2026 digital health exits analysis considers ventures across the globe, with selected analysis focusing on six key regions: North America, Asia Pacific, the Middle East, western Europe, South America (key markets), and Africa. A venture’s geographic location is determined by its initial country of incorporation. To be considered a digital health venture in this report, a company must be incorporated after 2002, qualify as Digital Health in accordance with Galen Growth’s taxonomy, and not be a subsidiary of a large corporation.
